title: Ibuprofen potentiates the in vivo antifungal activity of fluconazole against Candida albicans murine infection.
abstract: Candida albicans is the most prevalent cause of fungemia worldwide. Its ability to develop resistance in patients receiving azole antifungal therapy is well documented. In a murine model of systemic infection, we show that ibuprofen potentiates fluconazole antifungal activity against a fluconazole-resistant strain, drastically reducing the fungal burden and morbidity. The therapeutic combination of fluconazole with ibuprofen may constitute a new approach for the management of antifungal therapeutics to reverse the resistance conferred by efflux pump overexpression.
authors.affiliation: Department of Microbiology, Faculty of Medicine, University of Porto, Porto, Portugal CINTESIS-Center for Health Technology and Services Research, Faculty of Medicine, University of Porto, Porto, Portugal sqco@med.up.pt.
authors.forename: Sofia
authors.identifier: http://orcid.org/0000-0003-2899-6615
authors.initials: S
authors.lastname: Costa-de-Oliveira
authors.affiliation: Department of Microbiology, Faculty of Medicine, University of Porto, Porto, Portugal CINTESIS-Center for Health Technology and Services Research, Faculty of Medicine, University of Porto, Porto, Portugal.
authors.forename: Isabel M
authors.initials: IM
authors.lastname: Miranda
authors.affiliation: Department of Microbiology, Faculty of Medicine, University of Porto, Porto, Portugal CINTESIS-Center for Health Technology and Services Research, Faculty of Medicine, University of Porto, Porto, Portugal.
authors.forename: Ana
authors.initials: A
authors.lastname: Silva-Dias
authors.affiliation: Department of Microbiology, Faculty of Medicine, University of Porto, Porto, Portugal CINTESIS-Center for Health Technology and Services Research, Faculty of Medicine, University of Porto, Porto, Portugal.
authors.forename: Ana P
authors.initials: AP
authors.lastname: Silva
authors.affiliation: Department of Microbiology, Faculty of Medicine, University of Porto, Porto, Portugal CINTESIS-Center for Health Technology and Services Research, Faculty of Medicine, University of Porto, Porto, Portugal Burn Unit, Department of Plastic and Reconstructive Surgery, Hospital São João, Porto, Portugal.
authors.forename: Acácio G
authors.initials: AG
authors.lastname: Rodrigues
authors.affiliation: Department of Microbiology, Faculty of Medicine, University of Porto, Porto, Portugal CINTESIS-Center for Health Technology and Services Research, Faculty of Medicine, University of Porto, Porto, Portugal Burn Unit, Department of Plastic and Reconstructive Surgery, Hospital São João, Porto, Portugal Department of Microbiology, Hospital São João, Porto, Portugal.
authors.forename: Cidália
authors.initials: C
authors.lastname: Pina-Vaz
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D002176:Candida albicans / Q000187:drug effects / Q000235:genetics; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D025141:Drug Resistance, Fungal / Q000235:genetics; D004357:Drug Synergism; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use*; D005656:Fungal Proteins / Q000235:genetics / Q000378:metabolism; D007052:Ibuprofen / Q000627:therapeutic use*; D026901:Membrane Transport Proteins / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008826:Microbial Sensitivity Tests
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000935:Antifungal Agents; C094693:CDR1 protein, Candida albicans; D005656:Fungal Proteins; D026901:Membrane Transport Proteins; D015725:Fluconazole; D007052:Ibuprofen
references.citation: J Innate Immun. 2011;3(2):180-99
references.pmid: 21063074
references.citation: Diagn Microbiol Infect Dis. 2011 Oct;71(2):126-30
references.pmid: 21840673
references.citation: Expert Rev Anti Infect Ther. 2012 Jan;10(1):85-93
references.pmid: 22149617
references.citation: Am J Med. 2012 Jan;125(1 Suppl):S3-13
references.pmid: 22196207
references.citation: J Clin Microbiol. 2012 Sep;50(9):2846-56
references.pmid: 22740712
references.citation: Clin Microbiol Infect. 2013 Aug;19(8):E343-53
references.pmid: 23607326
references.citation: Infect Immun. 2014 Feb;82(2):532-43
references.pmid: 24478069
references.citation: Cell. 1991 Aug 23;66(4):807-15
references.pmid: 1715244
references.citation: Blood. 1992 Sep 15;80(6):1528-36
references.pmid: 1381629
references.citation: Clin Microbiol Rev. 1999 Oct;12(4):583-611
references.pmid: 10515904
references.citation: Antimicrob Agents Chemother. 2005 Jun;49(6):2226-36
references.pmid: 15917516
references.citation: Nat Rev Microbiol. 2005 Jul;3(7):547-56
references.pmid: 15953931
references.citation: J Antimicrob Chemother. 2005 Oct;56(4):678-85
references.pmid: 16115827
references.citation: Antimicrob Agents Chemother. 2006 Apr;50(4):1311-9
references.pmid: 16569846
references.citation: J Pharmacol Exp Ther. 2007 Jan;320(1):229-35
references.pmid: 17005917
references.citation: J Antimicrob Chemother. 2007 Feb;59(2):313-6
references.pmid: 17185297
references.citation: Rev Iberoam Micol. 2007 Sep 30;24(3):223-7
references.pmid: 17874860
references.citation: Eur J Clin Microbiol Infect Dis. 2008 May;27(5):365-74
references.pmid: 18204871
references.citation: Drug Resist Updat. 2008 Feb-Apr;11(1-2):25-31
references.pmid: 18325827
references.citation: Pediatrics. 2008 Dec;122(6):e1256-61
references.pmid: 19047225
references.citation: FEMS Yeast Res. 2009 Jun;9(4):626-33
references.pmid: 19385998
references.citation: FEMS Yeast Res. 2009 Jun;9(4):618-25
references.pmid: 19416368
references.citation: Inflammopharmacology. 2009 Dec;17(6):275-342
references.pmid: 19949916
references.citation: Antimicrob Agents Chemother. 2010 Apr;54(4):1476-83
references.pmid: 20086148
references.citation: PLoS Pathog. 2010;6(6):e1000939
references.pmid: 20532216